What weight loss injections do to your pancreas — and when to act

You've noticed stomach pain, here's how to read it

It starts as a nagging ache, somewhere in the upper abdomen. You took your injection a day or two ago, and now you're not sure whether this is the usual nausea that lots of people feel in the first couple of weeks, or something that needs attention. That distinction matters.

The gastrointestinal side effects of medicines like Mounjaro (tirzepatide) and Wegovy (semaglutide) are common and well-documented: nausea, loose stools, indigestion, constipation. These tend to be most noticeable after starting treatment or after a dose step, and they usually ease within a week or two as the body adjusts. The NHS tirzepatide medicines page lists them clearly alongside what you would normally expect.

Pancreatitis feels different. The hallmark is severe, persistent pain (often centred in the upper abdomen but reaching through to the back) that does not settle on its own, and may be accompanied by vomiting that does not bring relief. If the pain is that level of intensity, or if it is escalating, the right move is to contact a GP or go to A&E the same day. Do not try to manage through it at home waiting to see if it passes. For a fuller look at how pancreatitis presents in this context, the pancreatitis and weight loss injections page covers the clinical picture in more detail.

What the MHRA and clinical evidence say about frequency

In January 2026, the MHRA issued a Drug Safety Update for GLP-1 receptor agonist medicines, formally reconfirming acute pancreatitis as a recognised but infrequent side effect. The update was not new alarm, it was a scheduled review that reinforced existing prescriber guidance. These communications matter because they keep the risk clearly labelled on the product information, even when that risk is rare in absolute terms.

The large clinical trials behind Mounjaro and Wegovy (SURMOUNT-1 and STEP 1, both published in the New England Journal of Medicine) were designed partly to detect adverse events at scale. Pancreatic events were recorded and assessed. They occurred, but at low rates, and the trials did not establish a causal link between the medicines and chronic pancreatic disease in the broader population. For people with a personal or family history of pancreatitis, the prescribing picture is more cautious: this is one of the reasons a clinical assessment happens before any prescription is written, not as a box-ticking exercise but because it changes what is appropriate for that person.

There is a related, separate question about pancreatic cancer. The current evidence does not establish that GLP-1 medicines increase the risk of pancreatic cancer, and regulatory reviews in both the UK and Europe have not found a causal signal. If you want to read specifically about that evidence, the pancreatic cancer and weight loss injections page looks at the data directly.

When to get medical help, and what to do before that point

The clearest signal requiring same-day medical contact is severe, persistent abdominal pain that radiates to your back, particularly if it is accompanied by vomiting and does not settle. Other signs worth acting on promptly include jaundice (yellowing of the skin or whites of the eyes), dark urine, or any feeling that something is genuinely wrong in a way that goes beyond the digestive discomfort you have experienced before on these medicines.

For symptoms that are uncomfortable but not severe (mild nausea, loose stools, a sense of fullness) these are expected, especially early in treatment or after a dose change. Staying hydrated helps. Eating smaller portions, avoiding fatty or very rich food, and not lying down immediately after eating can all reduce their intensity. Your Patient Information Leaflet covers these practical steps; so does the guide to pancreas problems and weight loss injections on this site.

If you are unsure and it is not urgent, the prescribers at nume offer aftercare seven days a week, you do not need to wait until Monday to ask a clinical question. That said, if the pain is acute, please do not wait for an online reply: call 111 or go to A&E. Reporting any suspected side effect to the MHRA via Yellow Card is also encouraged, even if you are unsure whether the symptom is related to the medicine.

How prescribers assess your pancreatic risk before treatment starts

A legitimate prescription for a weight loss injection includes a structured clinical review. At nume, that review is carried out by a GPhC-registered Independent Prescriber who reads your consultation the same day, a real clinician checking your answers, not software making a binary decision. Questions about prior pancreatitis, gallbladder disease, digestive conditions and relevant family history are part of that assessment, because they genuinely affect whether a GLP-1 medicine is appropriate and which one might suit you better.

If you have had pancreatitis before, that does not automatically rule out treatment, but it is a conversation that needs to happen openly. The same applies if you have gallstones, gallbladder events are separately listed as a known risk of these medicines, and the two conditions can occasionally overlap in their presentation. Prescribers discuss this as part of suitability, not to deter people, but because a good clinical decision requires the full picture. You can read more about what the consultation looks at on the weight loss injections overview page, or explore the 3 weight loss injections available more broadly at our treatment consultation hub.